2 Followers SGX:BFK - Pharmesis Intl (SGD 0.33) PHARMESIS INTERNATIONAL LTD.
Sector: Health Technology, Industry: Pharmaceuticals: Generic

Add to WatchList

See related symbol P31


SGD 0.33    +0.0 (+0%)
Show Technical Chart | 1M    3M    6M    1Y    3Y    5Y         

24 Jan 2020


Overview

24 Jan 2020

52 Wk Range: 0.115 - 0.45

Day's Range: 0.33 - 0.33

Last Volume: 0

Current Yield: 0%

Projected Yield: 0%

Future Yield: [Friends Only]

Dividend Strength: [Friends Only]

24 Jan 2020

Metric BFK S.Median
Beta -0.01 0.09
VaR 76.07 34.03
E.Shortfall 128.3 43.92
Liquidity 143 17.58K

Fundamental

24 Jan 2020

PE: NA

Market Cap: 7.6M

Price Over Book: 0.56

Price Over Sales: 0.92

Return On Assets: -6.7%

Return On Equity: -9.3%

NAV Over Price: [Friends Only]

General

CEO: Xue Dan Wu

Founded Year: 2003

Headquarters: Chengdu

Shares Outstanding: 23M

Security Type: Stock

Useful Links
Homepage

Description

Pharmesis International Ltd. Is an investment holding company, which engages in the research, development, production, sale, and marketing of medicine and medicine formulated products for the treatment of illnesses relating to the liver and gall bladder. It operates through the following segments: Western Drugs, Traditional Chinese Medicine (TCM) Formulated Drugs, and Distribution. The Western Drugs segment involves in the chemically formulated drugs and is marketed under the Kinna brand. The TCM segment offers traditional Chinese medicine and is marketed under the Longlife brand. The Distribution segment consists of agency products and internally manufactured products which are marketed through the distribution arm. The company was founded on September 29, 2003 and is headquartered in Chengdu, China.